复方甘草酸苷在HBsAg阳性结核患者发生药物性肝损害中的防治作用  

Prevention and Treatment Effect of Compound Glycyrrhizin in 56 HBsAg Positive Patients with Tuberculosis

作　　者：孙鹏[1] 李娥[2] 邱杰文[1] 蔡妙龄[1] 

机构地区：[1]汕头大学医学院第二附属医院感染科 [2]汕头大学医学院第一附属医院感染科,广东汕头515041

出　　处：《汕头大学医学院学报》2006年第2期100-101,112,共3页Journal of Shantou University Medical College

摘　　要：目的：探讨复方甘草酸苷在HBsAg阳性结核患者发生药物性肝损害中的防治作用。方法：56例HBsAg阳性结核患者分为治疗组[在抗结核病药物的基础上加用复方甘草酸苷注射液60～80mL，静滴1次/d]和对照组[在抗结核药物的基础上加用肝泰乐注射液4 mL，静滴1次/d]。对两组发生肝损害的情况进行比较。结果：治疗组药物性肝损害5例（17．9％），对照组15例（53．6％）；治疗组肝损害程度低于对照组（P〈0．01）。结论：复方甘草酸苷可显著降低药物性肝损害的发生。Objective： To explore the prevention and treatment effect of compound glycyrrhizin in 56 HBsAg positive patients with tuberculosis. Methods： Fifty-six HBsAg positive patients with tuberculosis were divided into treatment group （compound glycyrrhizin injection from 60 to 80 mL by intravenous drip, once a day on the basis of given anti-tuberculosis medicine） and control group（glucurolactone injection 0.3 g by intravenous drip, once a day on the basis of given anti-tuberculosis medicine）. The liver damage level between two groups was compared. Results： There were 5 cases who had liver damage in treatment group（ 17.9% ）and 15 cases in control group（53.6% ）. The liver damage level in treatment group was lower than in control group（ P 〈 0.01）. Conclusion： Compound glycyrrhizin can evidently reduce the drug-induced liver damage.

关 键 词：药物性肝损害 结核 复方甘草酸苷 

分 类 号：R52[医药卫生—内科学] R969.3[医药卫生—临床医学]